CRISPR-Based Treatment Cures Genetic Blindness in Human Trial

common.volume$20,961

common.deadlineMar 12, 2026

Market Probability Chart

Forecast

AI Analysis Active

Live

Insufficient Data for Projection

common.about_results

Editas Medicine is preparing to release Phase 3 clinical trial results showing complete restoration of vision in patients with inherited retinal dystrophy using in-vivo CRISPR gene editing. The treatment represents the first FDA-approved curative genetic therapy for blindness, revolutionizing ophthalmology and genetic medicine.

common.select_outcome

common.buy_sharescommon.max_limit: 10,000

common.shares

common.avg_cost

50¢common.per_share

common.investing$5.00

common.potential_returncommon.if_resolves YES

$10.00

common.secured_by